Shopping Cart 0
Cart Subtotal
USD 0

KOL Perspectives: Histologic Healing in Crohn's disease

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

KOL Perspectives: Histologic Healing in Crohn's disease

Summary

This KOL Insight briefing focuses on KOLs views of Histologic Healing in Crohn's disease.

Questions topics-

- Use of histological assessment in clinical trials and practice in Crohn's disease

- Extrapolation of UC histology to UC

- Barriers to adoption of histology assessment in Crohn's disease

- Impact of histological data in therapy choice in Crohn's disease?Views on use of Geboes as an endpoint in Crohn's disease

- Views on Phase II sub-analysis data for filgotinib

Key Highlights

- Majority of KOLs state that histologic healing is not used to assess Crohn's disease patients in clinical practice

- Main barriers to adoption of histologic healing identified by KOLs include difficulty in accessing meaningful biopsy locations, as well as lack of data surrounding histology as a treatment goal

- Data showing moderate correlation between endoscopy and histology in Phase II does not impact on views of filgotinib efficacy.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our IBD key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during Q2 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on Histologic Healing in Crohn's disease

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Histology, Geboes score, extrapolation, Phase II


Companies

Gilead

Celgene

KOL Perspectives: Histologic Healing in Crohn's disease

Summary

This KOL Insight briefing focuses on KOLs views of Histologic Healing in Crohn's disease.

Questions topics-

- Use of histological assessment in clinical trials and practice in Crohn's disease

- Extrapolation of UC histology to UC

- Barriers to adoption of histology assessment in Crohn's disease

- Impact of histological data in therapy choice in Crohn's disease?Views on use of Geboes as an endpoint in Crohn's disease

- Views on Phase II sub-analysis data for filgotinib

Key Highlights

- Majority of KOLs state that histologic healing is not used to assess Crohn's disease patients in clinical practice

- Main barriers to adoption of histologic healing identified by KOLs include difficulty in accessing meaningful biopsy locations, as well as lack of data surrounding histology as a treatment goal

- Data showing moderate correlation between endoscopy and histology in Phase II does not impact on views of filgotinib efficacy.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our IBD key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during Q2 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on Histologic Healing in Crohn's disease

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Histology, Geboes score, extrapolation, Phase II


Companies

Gilead

Celgene